THE UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced the release of the first stem cell lines suitable for development into novel cell-based medicines.
Made available through the UK Stem Cell Bank at the National Institute of Biological Standards and Control, the stem cells are produced and quality controlled under European regulation.
They are "suitable for use as starting materials in manufacturing therapies for clinical trials, saving researchers precious time and effort," the MHRA said.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Mar 17
